Redeye returns with an update following AlzeCure’s Q1 earnings release. The company prepares its projects for clinical development, with a key focus on initiating a Phase IIa study with NeuroRestore ACD856 in Alzheimer’s patients in 2026, supported by the EIC grant. We reiterate our fair value range of SEK0.4-10, with a base case of SEK5.
LÄS MER
